MEDNAX (NYSE: MD) is expected to report Q1 earnings on May 2. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MEDNAX's revenues will expand 19.1% and EPS will grow 16.0%.
The average estimate for revenue is $503.3 million. On the bottom line, the average EPS estimate is $1.09.
Revenue details
Last quarter, MEDNAX logged revenue of $471.3 million. GAAP reported sales were 16% higher than the prior-year quarter's $404.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at $1.32. GAAP EPS of $1.32 for Q4 were 11% higher than the prior-year quarter's $1.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 39.3%, 80 basis points worse than the prior-year quarter. Operating margin was 21.9%, 70 basis points worse than the prior-year quarter. Net margin was 14.0%, 40 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $2.14 billion. The average EPS estimate is $5.47.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 174 members out of 180 rating the stock outperform, and six members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give MEDNAX a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $83.75.
Is MEDNAX the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MEDNAX to My Watchlist.
